

Kongress Beiträge

Regelmäßig nehmen wir nicht nur an den nationalen und internationalen Kongressen teil, sondern präsentieren eigene Arbeiten. Dies können interessante Fallpräsentationen oder auch wissenschaftliche Beiträge in Form von Postern oder Vorträgen sein. Unsere bisherigen Beiträge finden Sie aufgelistet nach Jahren im Folgenden.

Kongress Beiträge 2001-2004

- 1 Nüchel H, Dürig J, Halfmeyer K, Dührsen U: Overexpression of CXCR4 on B-CLL cells is associated with increased SDF-1 alpha plasma levels.
Onkologie 2001; 24: #63
- 2 Nüchel H, Dürig J, Schmücker U, Novotny JR, Noppene R, Dührsen U: Enhanced detection of malignant lymphoma in cerebrospinal fluid by multiparameter flow cytometry.
Onkologie 2001; 24: #216
- 3 Novotny JR, Rosenthal C, Nüchel H, Mahlmann S, Schmücker U, Staats B, Dührsen U: A fast, simple and cost effective method to circumvent the limitations of bone marrow dry tabs.
Onkologie 2001; 24: #213
- 4 Nüchel H, Noppene R, Novotny JR, Dührsen U: A-SHAP therapy for refractory and relapsing intermediate or high-grade Non-Hodgkin lymphoma.
Journal of Cancer research and clinical oncology 2002; 128: # 330
- 5 Nüchel H, Frey U, Aral N, Dürig J, Dührsen U, Siffert W: A germline polymorphism in the G protein b3 gene (GNB3) predicts the likelihood of relapse in patients with chronic lymphocytic leukaemia.
Onkologie 2002; 25: #604
- 6 Dürig J, Nüchel H, Hüttmann A, Hoelter T, Kruse E, Rudolph R, Kalhori N, Nusch A, Deaglio S, Malavasi F, Möröy T, Klein-Hitpass L, Dührsen U: Gene expression profiling in CD38+ versus CD38- B-cell chronic lymphocytic leukaemia.
Onkologie 2002; 25: #597
- 7 Mozek Ch, Metz K-A, Novotny J, Dechene A, Nüchel H, Dührsen U: Treatment of a follicular dendritic reticulum cell tumor (FDC-tumor) in a 65 year old woman.
Onkologie 2002; 25: #637
- 8 Nüchel H, Frey U, Aral N, Dürig J, Dührsen U, Siffert W: A germline polymorphism in the G protein b3 gene (GNB3) predicts the likelihood of relapse in patients with chronic lymphocytic leukaemia.
Blood 2002; 100: #2148
- 9 Dürig J, Nüchel H, Hüttmann A, Hoelter T, Deaglio S, Klein-Hitpass L, Dührsen U: Gene expression profiling in CD38+ versus CD38- B cell chronic lymphocytic leukaemia.
Blood 2002; 100: #1480
- 10 Nüchel H, Dürig J, Dührsen U: A retrospective single-center study of 62 patients with advanced multiple myeloma.
Onkologie 2003; 26: #714
- 11 Nüchel H, Dürig J, Hüttmann A, Kruse E, Hoelter T, Schmücker U, Halfmeyer K, Führer A, Moeroey T, Klein-Hitpass L, Dührsen U: The chemokine / chemokine receptor network in chronic lymphocytic leukaemia.
Onkologie 2003; 26: #841
- 12 Dürig J, Nüchel H, Cremer M, Klein-Hitpass L, Dührsen U: ZAP-70 expression is a prognostic factor in chronic lymphocytic leukaemia.
Onkologie 2003; 26: #847

- 13 Müller-Beisenhirtz H, Kasper C, Nüchel H, Dührsen U: Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study.
Onkologie 2003; 26: #896
- 14 Nüchel H, Dürig J, Hüttmann A, Kruse E, Hoelter T, Schmücker U, Halfmeyer K, Führer A, Möry T, Klein-Hitpass L, Dührsen U: The chemokine / chemokine receptor network in chronic lymphocytic leukemia.
Blood 2003; 102: #5112
- 15 Dürig J, Nüchel H, Klein-Hitpass L, Dührsen U: ZAP-70 expression is a prognostic factor in chronic lymphocytic leukaemia.
Blood 2003; 102: #5113
- 16 Frey UH, Nüchel H, Dobrev D, Manthey I, Sandalcioglu IE, Eisenhardt A, Worm K, Hauner H, Siffert W: Quantification of G Protein Gas subunit splice variants in different human tissues and cells using pyrosequencing.
Archives of Pharmacology 2004; 369: #178
- 17 Nüchel H, Frey U, Dürig J, Dührsen U, Siffert W: Methylenetetrahydrofolate reductase (MTHFR) gene 677C>T and 1298A>C haplotype: new prognostic factors in chronic lymphocytic leukaemia.
Journal of Cancer Research and Clinical Oncology 2004; 130: #317
- 18 Nüchel H, Frey U, Dürig J, Dührsen U, Siffert W: Methylenetetrahydrofolate reductase (MTHFR) gene 677C>T and 1298A>C haplotype: new prognostic factors in chronic lymphocytic leukaemia.
Journal of Clinical Oncology 2004; #6524
- 19 Nüchel H, Frey UH, Röth A, Dührsen U, Siffert W: Alemtuzumab induces apoptosis in vitro in B-Cells from patients with chronic lymphocytic leukaemia.
Onkologie 2004; 27: #705
- 20 Nüchel H, Meller D, Steuhl KP, Dührsen U: Anti-CD20 monoclonal antibody therapy in relapsed MALT Lymphoma of the conjunctiva.
Onkologie 2004; 27: #796
- 21 Wüstemeyer H, Nüchel H, Dührsen U, Steuhl KP, Meller D: Anti-CD20 monoklonale Antikörper als Therapie bei rezidivierenden MALT-Lymphomen der Bindehaut.
Der Ophthalmologe 2004, #191
- 22 Nüchel H, Frey UH, Dührsen U, Siffert W: Vitamin D receptor polymorphism: association with chronic lymphocytic leukemia outcome.
International Journal of clinical pharmacology and therapeutics 2004; 42/11: #621
- 23 Nüchel H, Rebmann V, Dürig J, Dührsen U, Grosse-Wilde H: HLA-G Expression is associated with a more aggressive, unfavorable outcome and immunosuppression in chronic lymphocytic leukaemia.
Blood 2004; 104: #2811
- 24 Nüchel H, Frey UH, Dührsen U, Siffert W: G Protein as subunit T393C polymorphism is associated with progression-free survival in chronic lymphocytic leukemia.
Blood 2004; 104: #4400

Kongress Beiträge 2005-2007

- 25 Aydin S, Nüchel H, Dührsen U: ASHAP plus rituximab for refractory or relapsed intermediate or high-grade non-Hodgkin's lymphomas: A retrospective single center analysis of 20 patients. *Onkologie* 2005; 28: #729
- 26 Nüchel H, Frey UH, Dührsen U, Siffert W: Association of a novel regulatory polymorphism (-938C>A) in the *BCL2* gene with disease progression in chronic lymphocytic leukemia. *Onkologie* 2005; 28:#82
- 27 Nüchel H, Frey UH, Sellmann L, Dürig J, Dührsen U, Siffert W: Association of a novel regulatory polymorphism (-938C>A) in the *BCL2* gene with disease progression in chronic lymphocytic leukemia. *Blood* 2005; 105:#2105
- 28 Rebmann V, Nüchel H, Dürig J, Dührsen U, Grosse-Wilde H: Association between HLA-G expression and unfavorable outcome of B-CLL patients. *Genes and Immunity* 6, S12. 2005
- 29 Nüchel H, Hilger AR, Grubert M, Röth A, Dührsen U: Pegylated liposomal doxorubicin and dexamethasone as salvage therapy for multiple myeloma: a prospective phase II single center study of 18 patient. *Onkologie* 2006; 29: #768
- 30 Nüchel H, Dührsen U, Siffert W: Impact of germline singular nucleotide polymorphisms in chronic lymphocytic leukaemia. *Onkologie* 2007; 30 (Supp.3): #182
- 31 Bachmann HS, Collins CH, Dührsen U, Siffert W, Nüchel H: Easy detection of *NPM1* exon 12 mutations in AML patients by pyrosequencing. *Onkologie* 2007; 30 (Supp.3): #391
- 32 Bachmann HS, Otterbach F, Callies R, Nüchel H, Bau M, Schmid KW, Siffert W, Kimmig R: The AA genotype of the regulatory *BCL2* promotor polymorphism (-938 C>A) is associated with favourable outcome in lymph node negative invasive breast cancer patients. *Onkologie* 2007; 30 (Supp.3): #397
- 33 Nüchel H, Collins CH, Sellmann L, Riemann K, Dührsen U, Siffert W: *CLLU1* is a CLL specific novel gene and high *CLLU1* expression is associated with poor outcome in B-CLL. *Onkologie* 2007; 30 (Supp.3): #603
- 34 Nüchel H, Collins CH, Riemann K, Dührsen K, Siffert W: The -871 C>T polymorphism in the Blys promotor region is associated with disease progression and survival in chronic lymphocytic leukemi. *Onkologie* 2007; 30 (Supp.3): #602
- 35 Sellmann L, Cyrull S, Nüchel H, Bollinger C, Boes T, Carpinteiro A, Dührsen U, Küppers R, Klein-Hitpass L, Dürig J: Gene dosage effects in B-chronic lymphocytic leukaemia with del 13q14. *Onkologie* 2007; 30 (Supp.3): #605
- 36 Heubner M, Otterbach F, Kasimir-Bauer S, Wimberger P, Collins CH, Dührsen U, Schmid KW, Siffert W, Kimmig R, Nüchel H: Association of the AA genotype of the regulatory *BCL2* promoter polymorphism (-938C>A) with better survival in ovarian cancer. *Onkologie* 2007; 30 (Supp.3): #226
- 37 Ortmann CA, Eisele L, Nüchel H, Klein-Hitpass L, Führer A, Dührsen U, Zeschnigk M: Epigenetic activation of *PRAME* in acute myeloid leukemia. *Experimental Hematology* 2007; 35(2): #113
- 38 Khandanpour C, Thiede C, Nüchel H, Lohmann D, Horsthemke B, Siffert W, Neubauer A, Grzeschik KH, Ehninger G, Dührsen U, Möröy T: A variant allele of the gene growth factor independence 1 (*GFI1*) is associated with acute myeloid leukemia. *Blood* 2007; 110: #13
- 39 Röth A, de Beer D, Nüchel H, Sellmann L, Dührsen U, Dürig J, Baerlocher GM: Significantly shorter telomeres in T-cells of *ZAP-70⁺/CD38⁺* patients with chronic lymphocytic leukemia

(CLL): An important role of T-cells in this subgroup of CLL?
Blood 2007; 110: #1120

- 40 Zenz T, Dührsen U, Döhner H, Siffert W, Stilgenbauer S, Nüchel H: Prognostic assessment of three single nucleotide polymorphisms (*BCL2* -938C>A, *MTHFR* 677C>T, *GNAS1* T393C) in chronic lymphocytic leukemia.
Blood 2007; 110: #2072

Kongress Beiträge 2008-2009

- 41 Bachmann HS, Frey UH, Riemann K, Schmitz KJ, Otterbach F, Callies R, Nüchel H, Siffert W: The high risk allele of a six-nucleotide insertion-deletion polymorphism in the *CASP8* promoter is associated with favorable outcome in multiple cancers.
J Clin Oncol 2008;26: #11073

- 42 Siffert W, Lehnerdt G, Franz P, Bankfalvi A, Nüchel H, Grehl S, Lang S, Schmid KW, Bachmann HS: The AA genotype of the regulatory *BCL2* promoter polymorphism (-938C>A) is associated with a favorable 5-year survival in oropharynx carcinoma patients
J Clin Oncol 2008; 26: #11051

- 43 Christoph S, Dührsen U, Nüchel H: Clofarabine for the treatment of patients with relapsed or refractory acute myeloid leukemia: Our own experience in 5 patients.
Onkologie 2008; 31 (Supp.4): #168

- 44 Nüchel H, Dührsen U, Flasshove M, Klein-Hitpass L, Siffert W, Frey UH: Association of a novel regulatory polymorphism in the *GNAS1* gene and the overall survival in acute myeloid leukemia.
Onkologie 2008; 31 (Supp.4): #171

- 45 Nüchel H, Frey UH, Sellmann L, Collins CH, Dührsen U, Siffert W: The Aiolos transcription factor is highly upregulated and inversely correlated with clinical progression in chronic lymphocytic leukemia.
Onkologie 2008; 31 (Supp.4): #197

- 46 Röth A, de Beer D, Nüchel H, Sellmann L, Dührsen U, Dürig J, Baelocher GM: Significantly shorter telomeres in T-cells from ZAP-70+/CD38+ patients with chronic lymphocytic leukemia.
Onkologie 2008; 31 (Supp.4): #210

- 47 Johansson P, Dührsen U, Nüchel H: Smudge cells on routine blood smears as predictor in chronic lymphocytic leukemia: a simple, fast, inexpensive and universally prognostic test.
Onkologie 2008; 31 (Supp.4): #232

- 48 Nüchel H, Switala M, Collins CH, Sellmann L, Siffert W, Grosse-Wilde H, Dührsen U, Rebmann V: High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia.
Onkologie 2008; 31 (Supp.4): #234

- 49 Nüchel H, Collins CH, Sellmann L, Dührsen U, Siffert W. FCRL2 expression is inversely associated with clinical progression in chronic lymphocytic leukemia.
Onkologie 2008; 31 (Supp.4): #235

- 50 Nüchel H, Rebmann V, Switala M, Dührsen U, Collins CH, Grosse-Wilde H: The prognostic significance of soluble NKG2D ligand in B cell chronic lymphocytic leukemia.
Onkologie 2008; 31 (Supp.4): #238

- 51 Wagner N, Haferlach T, Nüchel H, Gaiger A, Mayr C, Busch R, Döhner H, Stilgenbauer S, Hallek M, Fingerle-Rowson G: The CATT repeat polymorphism in the promoter of macrophage migration inhibitory factor (MIF) is associated with the frequency of 13q single deletions in human chronic lymphocytic leukemia.
Onkologie 2008; 31 (Supp.4): #239

- 52 Liebisch P, Sixt S, Bachmann H, Frey U, Peters J, Döhner H, Dührsen U, Nüchel H: Elevated circulating proteasome levels at diagnosis are associated with poor outcome in multiple myeloma.
Onkologie 2008; 31 (Supp.4): #521

- 53 Bachmann HS, Novotny J, Sixt S, Liebisch P, Frey U, Peters J, Dührsen U, Siffert W, Nüchel H: A novel functional SNP in PSMA6 is associated with multiple myeloma and poor outcome

- independent of circulating proteasome serum levels.
Onkologie 2008; 31 (Supp.4): #524
- 54 Khandanpour S, Bartels M, Sellmann L, Collins CH, Nowrousian MR, Dührsen U, Nüchel H:
Thiamin-responsive megaloblastic anemia (TRMA) – A novel mutation in exon 4 of the
SLC19A2 gene.
Onkologie 2008; 31 (Supp.4): #603
- 55 Nüchel H, Frey UH, Sellmann L, Collins CH, Dührsen U, Siffert W: The Aiolos transcription
factor is highly upregulated and inversely correlated with clinical progression in chronic
lymphocytic leukemia.
Blood 2008; 112: #206
- 56 Bachmann HS, Novotny J, Sixt S, Liebisch P, Frey U, Peters J, Dührsen U, Siffert W, Nüchel H:
A functional promoter polymorphism (-8C>G) of the proteasome subunit $\alpha 6$ SNP in PSMA6 is
associated with multiple myeloma and poor outcome independent of circulating proteasome
serum levels.
Blood 2008; 112: #1668
- 57 Hills M, Röth A, Nüchel H, Horsman D, Dürig J, Gascoyne RD, Lansdorp PM: High prevalence
of TERT mutations in chronic lymphocytic leukemia.
Blood 2008; 112: #3126
- 58 Sellmann L, de Beer D, Bartels M, Nüchel H, Dührsen U, Dürig, Baerlocher G, Röth A: Shorter
telomeres are associated with the unfavourable chromosomal aberrations del 17p and del 11q
in chronic lymphocytic leukemia (CLL).
Blood 2008; 112: #3131
- 59 Liebisch P, Langer C, Döhner H, Dührsen U, Nüchel H: Value of the combination of molecular
cytogenetics and international staging system (ISS) to predict outcome of patients with multiple
myeloma after high dose chemotherapy and autologous stem cell transplantation.
Onkologie 2009; 32 (Supp.4): #296
- 60 Weschenbach-Pohl T, Nüchel H, Dührsen U, Novotny J: Comorbidity indices do not predict
requirement of ICU-treatment in haematological.
Onkologie 2009; 32
- 61 Aisenbrey A, Nüchel H, Dührsen U, Novotny J: Impact of comorbidity on outcome in AML:
Comparison of two comorbidity.
Onkologie 2009; 32 (Supp.4): #425
- 62 Nüchel H, Collins CH, Sellmann L, Dürig J, Siffert W, Dührsen U: T cell leukemia/lymphoma 1
(TCL1) expression is correlated with clinical progression in chronic lymphocytic.
Onkologie 2009; 32 (Supp.4): #425
- 63 Matschke J, Eisele L, Sellmann L, Dührsen U, Dürig J, Nüchel H: Abnormal free light chain ratios
are significantly associated with clinical progression in chronic lymphocytic leukemia.
Onkologie 2009; 32 (Supp.4): #708
- 64 Bartels M, Sellmann L, de Beer D, Nüchel H, Dührsen U, Dürig J, Baerlocher G, Röth A:
Correlation Of Telomere Length And Number Of Chromosomal Aberrations In.
Onkologie 2009; 32 (Supp.4): #717
- 65 Wagner N, Busch R, Hajali Z, Haferlach C, Schnittger S, Nüchel H, Eigenberger K, Gaiger A,
Mayr C, Hardt C, Döhner H, Stilgenbauer S, Hallek M, Fingerle-Rowson G: The CATT repeat
polymorphism in the promotor of macrophage migration inhibitory factor (MIF) is not associated
with incidence or clinical course of chronic lymphocytic leukemia.
Onkologie 2009; 32 (Supp.4): #720
- 66 Matschke J, Kordelas L, Azeh I, Novotny J, Dührsen U, Nüchel H: Hydroxyurea as a cause of
drug fever: a rare but important.
Onkologie 2009; 32 (Supp.4): #195
- 67 Khandanpour S, Erbel R, Dührsen U, Nüchel H: ST-elevated myocardial infarction in a patient
with Thiamin-responsive megaloblastic anaemia (TRMA) presenting a novel mutation in exon 4
of the SLC19A2 gene.
Onkologie 2009; 32 (Supp.4): #227

68 Matschke J, Noppeney R, Penndorf V, Rath P, Dührsen U, Nüchel H: Palatal mucormycosis in a patient with relapse of acute lymphoblastic leukemia: an infrequent and fatal diagnosis. *Onkologie* 2009; 32 (Supp.4): #521

69 Novotny J, Aisenbrey A, Nüchel H, Dührsen U: Comorbidity is an independent prognostic factor in AML: Comparison of two comorbidity. *Blood* 2009; 114: #3106

Kongress Beiträge 2010-2011

70 Matschke J, Eisele L, Sellmann L, Dührsen U, Dürig J, Nüchel H: Abnormal free light chain ratios in chronic lymphocytic leukemia: a new prognostic factor? *Blood* 2010; 114: #1237

71 Sellmann L, Scholtysik R, Nüchel H, Boes T, Carpinteiro A, Dührsen U, Klein-Hitpass L, Dürig, Küppers R: Gene dosage effects in B-chronic lymphocytic leukemia with. *Blood* 2009; 114: #2640

72 Nüchel H, Switala M, Ochsenfarth C, Dürig J, Horn P, Dührsen U, Rebmann V: High soluble MICA levels are associated to MICA-129 val/val genotypes and poor treatment free survival in chronic lymphocytic leukemia. *Onkologie* 2010; 33 (Supp.6): #158

73 Kapp J, Ochsenfarth C, Switala M, Frey UH, Sellmann L, Dürig J, Horn P, Dührsen U, Rebmann V, Nüchel H: Association of HLA-G haplotype risk model with treatment free survival in chronic lymphocytic leukemia patients. *Onkologie* 2010; 33 (Supp.6): #165

74 Wree A, Canbay A, Müller-Beissenhertz H, Gerken G, Dührsen U, Lammert F, Nüchel H: Case report: Excessive bilirubin elevation in a patient with hereditary spherocytosis and combined ABCB11 gene variants. *Onkologie* 2010; 33 (Supp.6): #179

75 Distelmaier L, Reumkens M, Hettenkofer T, Müller-Beissenhertz H, Noppeney R, Zotz R, Dührsen U, Nüchel H, Böhm S: Acquired factor X deficiency in a patient with amyloid light chain amyloidosis. *Onkologie* 2010; 33 (Supp.6): #826

76 Kordelas L, Liebisch P, Beelen DW, Dührsen U, Nüchel H: Prognostic scoring system for multiple myeloma patients undergoing high-dose therapy with autologous stem cell transplantation. *Onkologie* 2010; 33 (Supp.6): #834

77 Aydin S, Grabellus F, Ebeling P, Möllmann M, Eisele L, Nüchel H, Dürig J: The impact of CD38 in the CLL NOD/SCID xenograft model. *Onkologie* 2010; 33 (Supp.6): #673

78 Volbracht A, Novotny J, Ochsenfarth C, Switala M, Frey UH, Horn P, Dührsen U, Rebmann V, Nüchel H: Association of HLA-G haplotype risk model with overall survival in acute myeloid leukemia patients. *Onkologie* 2010; 33 (Supp.6): #727

79 Kapp J, Ochsenfarth C, Switala M, Frey UH, Sellmann L, Dürig J, Horn P, Dührsen U, Rebmann V, Nüchel H: Association of HLA-G haplotype risk model with treatment free survival in chronic lymphocytic leukemia patients. *Blood* 2010; 116: #2418

80 Volbracht A, Novotny J, Ochsenfarth C, Switala M, Frey UH, Horn P, Dührsen U, Rebmann V, Nüchel H: Association of HLA-G haplotype risk model with overall survival in acute myeloid leukemia patients. *Blood* 2010; 116: #2169

81 Nüchel H, Ochsenfarth C, Sellmann L, Dürig J, Dührsen U, Frey UH: A new microRNA risk model for prediction of clinical outcome in chronic lymphocytic leukemia. *Blood* 2010; 116: #3592

82 Distelmaier L, Kharaman A, Noppeney R, Dührsen U, Nüchel H: Cardiac chloroma in a patient

with relapsed acute myeloid leukemia
Onkologie 2011; 34 (Supp.6): #302

- 83 Johansson P, Nüchel H, Dührsen U, Dürig J: Percentage of smudge cells on routine blood smears predict time to first treatment and overall survival in patients with Binet A chronic lymphocytic leukemia
Onkologie 2011; 34 (Supp.6): #493

Kongress Beiträge 2012-2013

- 84 Bulian P, Shanafelt TD, Pepper C, Fegan C, Del Poeta G, Gaidano G, Rossi D, Baldini L, Cro L, Nüchel H, Burger JA, Gattei V: Prognostic Relevance of CD49d Expression On B Leukemic Cells in Chronic Lymphocytic Leukemia. Meta-Analysis of Published and unpublished Individual Data From 3146 Patients Blood 2012; 116: 3871

- 85 Sellmann L, Scholtysik R, Klein-Hitpass L, Nüchel H, Dührsen U, Röth A: Significance of chromosomal aberrations and HMGA2 expression in paroxysmal nocturnal hemoglobinuria (PNH) Onkologie 2012; 35 (Supp. 6): #733

- 86 Nüchel H, May T, Opalka B, Dührsen U and Rebmann V
The two sides of NKG2D ligand expression in AML: the peripheral blood and the bone marrow microenvironment. Wagner B., Albrecht F, Radtke S, Giebel B, Horn PA, Dürig J, Volbracht A, Mildred Scheel Cancer Conference (Königswinter, 05-07.06.2013).

- 87 CD49d Is The Strongest Flow Cytometry-Based Predictor Of Overall Survival In Chronic Lymphocytic Leukemia
Blood 2013; Abstract 672